In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...
BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and ...
“These additional results build upon the robust efficacy data we observed in the Phase 2a trial and further expand the growing body of evidence supporting RAP-219’s potential as a best-in-class ...
--Rapport Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results